Drug Development

Results abstract submitted from phase 2 trial of non-Hodgkin lymphoma drug

Published in Cancer Weekly, September 7th, 2004

Spectrum Pharmaceuticals, Inc. (SPPI) announced that an abstract from the ongoing phase 2 trial evaluating elsamitrucin as a single agent for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL, cancer of the lymphatic system) has been submitted for presentation at an American Society of Hematology (ASH) meeting.

The abstract, entitled "A multi-center, open-label, non-randomized Phase II study of elsamitrucin (SPI-28090) in patients with relapsed or refractory non-Hodgkin's lymphoma," presents preliminary data from patients with advanced (stage 3 or I4) NHL, all of whom had failed at least 2 (and as many as 9) prior treatment regimens. Results were...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry